A million-dose success for Nepal: insights from Nepal’s national vaccine deployment plan against COVID-19

Bhattarai, Suraj; Dhungana, Jaya

doi:10.1093/jtm/taab027

Cited by 8 publications

(9 citation statements)

References 5 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the efficacy rate of different vaccines against different variants of COVID-19 has been varied [ 16 ]. COVID-19 vaccination rolled out in Nepal on 27 th January 2020 with frontline workers including health workers and security personnel being vaccinated in the first phase [ 17 ]. The vaccine administered was ChAdOx1 nCoV-19 (Covishield vaccine) which is an adenovirus vector vaccine [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study

Subedi¹,

Paudel²,

Regmi³

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Introduction The study aimed at exploring the adverse events following immunization (AEFI) and their incidences among health workers in three different districts of central and western Nepal following the first dose of Covishield vaccine,. It also aimed at studying the association of AEFI with demographic and clinical characteristics of vaccinees, pre-vaccination anxiety level and prior history of COVID-19 infection (RT- PCR confirmed) status. Materials and methods This was a cross-sectional study carried out via face-to-face or telephonic interview among 1006 health workers one week after receiving their first dose of the Covishield vaccine. Incidence of adverse events was calculated in percentage while Chi-square Test was used to check the association of AEFI with independent variables. Logistic regression was used to find out the adjusted odd’s ratio at 95% CI. Results Incidence of AEFI was 79.8% with local and systemic AEFI being 68.0% and 59.7% respectively. Injection site tenderness was the commonest manifestation. Local and systemic symptoms resolved in less than one week among 96.8% and 98.7% vaccinees respectively. Females were more likely to develop AEFI than males (AOR = 1.7, 95% CI = 1.2–2.4). Vaccinees aged 45–59 years were 50% less likely to develop AEFI as compared to those aged less than 30 years (AOR 0.5, 95% CI = 0.3–0.8). Most of the vaccinees had not undergone RT-PCR testing for COVID-19 (59.8%). Those who were not tested for COVID-19 prior were 1.5 odds more likely to develop AEFI compared to those who were negative (AOR = 1.5, 95% CI = 1.1–2.1). Conclusion More than two-third of the vaccinees developed one or more forms of adverse events, but most events were self-limiting. Females and young adults were more prone to develop AEFI.

show abstract

Section: Introductionmentioning

confidence: 99%

Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study

Subedi¹,

Paudel²,

Regmi³

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…No vaccinations have been initiated for children below 12 years of age. Nepal used six different vaccine formulations: Vero Cell, COVISHIELD, AstraZeneca (Japanese and Swedish), Moderna, Pfizer, and Janssen [ 25 ].…”

Section: Resultsmentioning

confidence: 99%

How an Outbreak of COVID-19 Circulated Widely in Nepal: A Chronological Analysis of the National Response to an Unprecedented Pandemic

Pandey

Tun

Pandey

et al. 2022

Life

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first COVID-19 case was reported in Wuhan, China, in December 2019. In March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic. The first COVID-19 case in Nepal was reported in January 2020 in a Nepalese man who had returned from Wuhan to Nepal. This study aims to evaluate the government of Nepal’s (GoN) response to the COVID-19 pandemic and explore ways to prevent COVID-19 and other pandemic diseases in the future. As of May 2022, a total of 979,140 cases and 11,951 deaths associated with COVID-19 have been reported in Nepal. To prevent the spread of the virus, the GoN initiated various preventive and control measures, including lockdown strategies. The effects of COVID-19 are expected to persist for many years; the best strategies a resource-limited country such as Nepal can implement to control pandemic diseases such as COVID-19 in the pre-vaccine stage are to increase testing, tracing, and isolation capacity.

show abstract

“…Nepal deployed COVID-19 vaccination on January 27, 2021, starting with Oxford-AstraZeneca (Covishield) vaccination for adults and elderly. 4 The mRNA-based vaccines were introduced in late 2021, for children 12–17 years ( www.covid19.mohp.gov.np ). However, there are no official publications regarding COVID-19 vaccination associated adverse events following immunization (AEFI).…”

Section: To the Editorsmentioning

confidence: 99%

Delayed-onset Anaphylaxis After mRNA-Based COVID-19 Vaccination in an Adolescent Male

Shrestha

Bhattarai

Dhungana

et al. 2022

Pediatric Infectious Disease Journal

Self Cite

View full text Add to dashboard Cite

show abstract

A million-dose success for Nepal: insights from Nepal’s national vaccine deployment plan against COVID-19

Cited by 8 publications

References 5 publications

Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study

Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study

How an Outbreak of COVID-19 Circulated Widely in Nepal: A Chronological Analysis of the National Response to an Unprecedented Pandemic

Delayed-onset Anaphylaxis After mRNA-Based COVID-19 Vaccination in an Adolescent Male

Contact Info

Product

Resources

About